How is QQQ stock faring? The Invesco QQQ ETF is down 0.58% in the past 5 days but has risen about 40% over the past year. According to TipRanks’ unique ETF analyst
How is QQQ stock faring? The Invesco QQQ ETF is down 0.58% in the past 5 days but has risen about 40% over the past year. According to TipRanks’ unique ETF analyst
JPMorgan analyst Chris Schott lowered the firm’s price target on Biogen to $240 from $270 and keeps a Neutral rating on the shares ahead of the Q1 report on April
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Biogen (BIIB – Research Report), KalVista Pharmaceuticals (KALV – Research Report) and PTC Therapeutics (PTCT – Research Report).
Biogen (BIIB)
J.P. Morgan analyst Chris Schott maintained a Hold rating on Biogen today and set a price target of $240.00. The company’s shares closed last Wednesday at $201.55, close to its 52-week low of $200.65.
According to TipRanks.com, Schott is a 3-star analyst with an average return of
Biogen has an analyst consensus of Moderate Buy, with a price target consensus of $289.32, representing a 42.5% upside. In a report issued on March 31, Wells Fargo also maintained a Hold rating on the stock with a $240.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
KalVista Pharmaceuticals (KALV)
In a report released today, Serge Belanger from Needham maintained a Buy rating on KalVista Pharmaceuticals, with a price target of $35.00. The company’s shares closed last Wednesday at $11.93.
According to TipRanks.com, Belanger is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for KalVista Pharmaceuticals with a $32.67 average price target.
PTC Therapeutics (PTCT)
Wells Fargo analyst Tiago Fauth maintained a Buy rating on PTC Therapeutics today and set a price target of $37.00. The company’s shares closed last Wednesday at $26.91.
According to TipRanks.com, Fauth has 0 stars on 0-5 stars ranking scale with an average return of
PTC Therapeutics has an analyst consensus of Hold, with a price target consensus of $29.11.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BIIB:
How is SPY stock faring? The SPDR S&P 500 ETF Trust is up 0.94% in the past 5 days and has risen about 29% over the past year. According to TipRanks’ unique
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Harmony Biosciences Holdings (HRMY – Research Report), Recursion Pharmaceuticals (RXRX – Research Report) and Biogen (BIIB – Research Report) with bullish sentiments.
Harmony Biosciences Holdings (HRMY)
Needham analyst Ami Fadia maintained a Buy rating on Harmony Biosciences Holdings today and set a price target of $50.00. The company’s shares closed last Monday at $29.84.
According to TipRanks.com, Fadia is a 3-star analyst with an average return of
Harmony Biosciences Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $41.33.
See Insiders’ Hot Stocks on TipRanks >>
Recursion Pharmaceuticals (RXRX)
In a report released today, Gil Blum from Needham maintained a Buy rating on Recursion Pharmaceuticals, with a price target of $17.00. The company’s shares closed last Monday at $9.00.
According to TipRanks.com, Blum is a 4-star analyst with an average return of
Currently, the analyst consensus on Recursion Pharmaceuticals is a Moderate Buy with an average price target of $17.00.
Biogen (BIIB)
In a report issued on April 4, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen, with a price target of $326.00. The company’s shares closed last Monday at $204.95, close to its 52-week low of $202.18.
According to TipRanks.com, Abrahams is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biogen with a $291.00 average price target, which is a 42.7% upside from current levels. In a report issued on April 1, Morgan Stanley also maintained a Buy rating on the stock with a $346.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on HRMY: